"10.1371_journal.pone.0043143","none","2012-08-15T00:00:00Z","Jerzy Jaroszewicz; Thomas Reiberger; Dirk Meyer-Olson; Stefan Mauss; Martin Vogel; Patrick Ingiliz; Berit Anna Payer; Matthias Stoll; Michael P Manns; Reinhold E Schmidt; Robert Flisiak; Heiner Wedemeyer; Markus Peck-Radosavljevic; Jürgen Rockstroh; Markus Cornberg","Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University Vienna, Vienna, Austria; Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany; Center for HIV and Hepatogastroenterology, Düsseldorf, Germany; Department of Internal Medicine I, University of Bonn, Bonn, Germany; Medical Center for Infectious Diseases (MIB), Berlin, Germany; Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland; German Center for Infectious Disease Research (DZIF)","Conceived and designed the experiments: JJ MPM HW MC. Performed the experiments: JJ TR DMO SM MV PI BP MS. Analyzed the data: JJ HW MC. Contributed reagents/materials/analysis tools: JJ TR DMO SM MV PI BP MS MPM RES RF HW MPR JR MC. Wrote the paper: JJ HW MC. Drafting the article or critically revising it and final approval: JJ TR DMO SM MV PI BAP MS MPM RES RF HW MPR JR MC.","The authors have the following conflicts: Lamivudine, GlaxoSmithKline (GSK); Tenofovir and Emtricitabine Gilead; HBsAg test, Abbott, Roche, Siemens. Dr. Jaroszewicz received lecture fees or travel grants from Roche, Gilead and Abbott. Dr. Reiberger received support from Roche (travel grant, lecture fee, grant support), MSD (travel grant, lecture fee) and Gilead (travel grant, grant support). Dr. Meyer-Olson received lecture fees or travel grants from Abbott, Bristol Myers-Squibb, Boehringer Ingelheim, Chugai, Pfizer, Roche. Dr. Mauss received lecture fees Abbott, BMS, Gilead, Janssen, MSD, Roche, advisory board BMS, Gilead, Janssen, Roche. Dr. Vogel has been employed at Janssen-Cilag since June 2011. Dr. Ingiliz has received lecture fees/consultancy fees from Roche, MSD, Gilead, BMS, Abbott, Tibotec. Dr. Payer received support from Roche (grants, lecture fees), MSD (travel grants) and Janssen (travel grants). Dr. Stoll received lecture fees and/or consult fees by Abbott, BMS, Boehringer-Ingelheim, Glaxo-Smith-Kline, ViiV-Healthcare, Roche, Gilead, Janssen-Cilag, Tibotec, Pfizer, and Merck, Sharp & Dohme. Dr. Manns received grants, lectural fees and/or consult fees from GSK, Gilead, Novartis, BMS, and Abbott. Dr. Schmidt received grants lecture fees or consult fees from Gilead, Abbott and Roche. Dr. Flisiak received advisory Board fee from Gilead; Lecture fees from Gilead, Abbott and Roche. Dr. Wedemeyer received grants, lectural fees and/or consult fees from Gilead, Novartis, BMS, and Abbott. Dr. Wedemeyer is also Academic Editor of PLoS ONE. Dr. Peck-Radosavljevic received lecture fee/advisory board from Roche, BMS, Gilead, speaker fees/consulting fees from MSD and grant support from Roche and MSD. Dr. Rockstroh received lecture fees and consult fees from Abbott, BMS, Boehringer, Gilead, GSK, Janssen, Merck, Roche Tibotec, and ViiV. Dr. Cornberg received lecture fees and/or consult fees from GSK, Gilead, Novartis, BMS, Roche, MSD and grant support from Roche and MSD. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","08","Jerzy Jaroszewicz","JJ",15,TRUE,4,8,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
